ACC 2019
Read the full Report (pdf)
American College of Cardiology 16–18 March 2019, New Orleans, USA
Featured articles
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
CONTENTS
Online First
Acute and Stable Ischaemic Heart Disease
Patients with polyvascular disease significantly undertreated with lipid lowering therapies
DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups
Arrhythmias and Clinical Electrophysiology
Diagnosing cardiac sarcoidosis with endomyocardial biopsies
Substantial impact of temporary interruptions of warfarin versus DOAC
Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin
Smartwatch can detect atrial fibrillation with high degree of accuracy
Congenital Heart Disease
Higher incidence arrhythmia post-percutaneous closure of secundum ASD in patients >60 years
Unplanned hospital readmission is common after congenital cardiac surgery
Heart Failure and Cardiomyopathies
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment
High 5-year survival rates for older HF patients without initial severe comorbidity
Pulmonary Arterial Hypertension and Venous Thromboembolism
Apixaban is safe and effective in real-world setting for treatment of venous thromboembolism
Interventional Cardiology
TAVR superior and non-inferior to SAVR in low-risk patients
Immediate angiography not better than delayed angiography in non-STEMI cardiac arrest patients
Ticagrelor monotherapy safe after dual antiplatelet therapy
P2Y12 inhibitor monotherapy is a novel antiplatelet strategy after short duration DAPT
Vascular Medicine
Similar MACE rates but higher all-cause mortality in PAD patients with diabetes
Lower rates stroke/SE with DOACs in frail non-valvular AF patients
